On Mar. 14, 2025, Sanofi announced the immediate adoption of influenza strains selected by the U.S. Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the U.S.

Sanofi has already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications.

Sanofi plans to begin shipping flu vaccines this summer so that health systems, hospitals, pharmacies, physician practices, nursing homes and other facilities can begin administering vaccines at the onset of the next flu season.

In addition to declining vaccination rates, the U.S. is currently experiencing one of the worst flu seasons in decades and rates of flu-related hospitalizations are at a 15-year high. According to estimates by the U.S. Centers for Disease Control and Prevention (CDC), there have been 40 million illnesses, 520,000 hospitalizations and 22,000 deaths from flu through the week ending March 1.